var data={"title":"AbobotulinumtoxinA (Dysport): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">AbobotulinumtoxinA (Dysport): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/392070?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=abobotulinumtoxina-dysport-patient-drug-information\" class=\"drug drug_patient\">see &quot;AbobotulinumtoxinA (Dysport): Patient drug information&quot;</a> and <a href=\"topic.htm?path=abobotulinumtoxina-dysport-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;AbobotulinumtoxinA (Dysport): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9605326\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Distant spread of toxin effect:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Postmarketing reports indicate that the effects of all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life-threatening, and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity, but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses, including upper limb spasticity in children, and in approved indications, cases of spread of effect have been reported at doses comparable to or lower than the maximum recommended total dose.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7999220\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Dysport;</li>\n      <li>Dysport (Glabellar Lines) [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51235505\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Dysport Therapeutic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7999304\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Neuromuscular Blocker Agent, Toxin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9605588\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cervical dystonia:</b> IM: Initial: 500 units divided among affected muscles in toxin-na&iuml;ve or toxin-experienced patients. May re-treat at intervals of &ge;12 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Dosage adjustments:</i> Adjust dosage in 250-unit increments; do not administer at intervals &lt;12 weeks; dosage range used in studies: 250 to 1,000 units</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Glabellar lines:</b> Adults &lt;65 years: IM: Inject 10 units into each of 5 sites (2 injections in each corrugator muscle and 1 injection in the procerus muscle) for a total dose of 50 units; do not administer at intervals &lt;3 months; efficacy has been demonstrated with up to 4 repeated administrations</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Spasticity:</b> IM: Individualize dose based on patient size, number and location of muscle involvement, severity of spasticity, local muscle weakness, response to prior treatment, and/or adverse reaction history. May repeat therapy at intervals &ge;12 weeks; in clinical studies, the majority of patients were re-treated between 12 to 16 weeks; however, some patients had a longer duration of response (eg, 20 weeks). For upper limb spasticity, total doses of 500 and 1,000 units divided among selected muscles were used in clinical trials. For lower limb spasticity, total doses of 1,000 and 1,500 units divided among selected muscles were used in clinical trials. The maximum recommended total dose (upper and lower limbs combined) is 1,500 units.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Upper limbs:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Brachialis: 200 to 400 units (1 to 2 injections per muscle)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Brachioradialis: 100 to 200 units (1 to 2 injections per muscle)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Biceps brachii: 200 to 400 units (1 to 2 injections per muscle)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Flexor carpi radialis: 100 to 200 units (1 to 2 injections per muscle)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Flexor carpi ulnaris: 100 to 200 units (1 to 2 injections per muscle)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Flexor digitorum profundus: 100 to 200 units (1 to 2 injections per muscle)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Flexor digitorum superficialis: 100 to 200 units (1 to 2 injections per muscle)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Pronator teres: 100 to 200 units (1 injection per muscle)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lower limbs:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Flexor digitorum longus: 130 to 200 units (1 to 2 injections per muscle)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Flexor halluces longus: 70 to 200 units (1 injection per muscle)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gastrocnemius, medial head: 100 to 150 units (1 injection per muscle)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gastrocnemius, lateral head: 100 to 150 units (1 injection per muscle)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Soleus: 330 to 500 units (3 injections per muscle)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Tibialis posterior: 200 to 300 units (2 injections per muscle)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anal fissure (off-label use): </b>IM: 90 to 150 units in 2 divided doses injected into the internal anal sphincter on each side of the anterior midline (Brasinda 2004; Yiannakopoulou 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Sialorrhea (off-label use):</b> Intraglandular (Ventral) (off-label route): 15 to 75 units injected per gland (submandibular, parotid or both) either unilaterally or bilaterally with intervals of 4 to 6 months between treatments (Reddihough 2010; Vashishta 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Tardive dyskinesia (off-label use): </b> IM: 20 to 50 units injected per site (total dosage range: 80 to 100 units). Dose, duration, and number of injections are dependent on muscle size and severity (Hennings 2008; Rapaport 2000). Subsequent doses up to 80 units have been used in order to find the optimum dosage (Slotema 2008). Additional data may be necessary to further define the role of abobotulinumtoxinA in the treatment of this condition.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48838379\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=abobotulinumtoxina-dysport-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;AbobotulinumtoxinA (Dysport): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lower limb spasticity:</b>\n      <i> Children &ge;2 years and Adolescents:</i> IM: Individualize dose based on patient size, number and location of muscles involved, severity of spasticity, local muscle weakness, response to prior treatment and/or adverse reaction history. May repeat therapy at intervals &ge;12 weeks; in clinical studies, the majority of patients were re-treated between 16 to 22 weeks; however, some patients had a longer duration of response.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Total dose per treatment session: 10 to 15 units/kg per limb. Maximum total dose per treatment session: 15 units/kg for unilateral injections, 30 units/kg for bilateral injections, or 1,000 units, whichever is less. Divide total dose administered between the affected muscles; distribute dose across &gt;1 injection site in any single muscle if possible; do not administer &gt;0.5 mL in any single injection site. Recommended dose range per muscle per limb:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrocnemius: 6 to 9 units/kg (up to 4 injections per muscle per limb)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Soleus: 4 to 6 units/kg (up to 2 injections per muscle per limb)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9605589\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cervical dystonia:</b> Refer to adult dosing. No specific adjustment recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Glabellar lines:</b> Not recommended in patients &ge;65 years of age.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Spasticity:</b> Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9605590\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment unlikely as abobotulinumtoxin A is not expected to be present in peripheral blood at recommended doses following intramuscular (IM) injection. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9605591\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment unlikely as abobotulinumtoxin A is not expected to be present in peripheral blood at recommended doses following intramuscular (IM) injection. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9605595\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intramuscular: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dysport: 300 units (1 ea); 500 units (1 ea) [contains albumin human, milk protein]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dysport (Glabellar Lines): 300 units (1 ea [DSC]) [contains albumin human, milk protein]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9605328\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9605327\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125274s109lbl.pdf#page=30&amp;token=xQJV5Tov+soBfbZnrE0L38u2/igp3JjgxyR9Bu/4QvcdF608pofddFbTWmFLYWYyiqNy+X/x79cxgTmnIdmfHccE4s9PBmBRpXViNOwL48YyZhjjtwr7SVWrM2vN8kpl&amp;TOPIC_ID=9195\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125274s109lbl.pdf#page=30</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9605593\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cervical dystonia: Use an appropriately sized gauge needle to administer intramuscularly. Limiting the dose injected into the sternocleidomastoid muscle may reduce the occurrence of dysphagia. Simultaneous EMG-guided application may be helpful in locating active muscle not identified by physical examination alone.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glabellar lines: Use a 30-gauge needle to administer intramuscularly. Apply pressure on the superior medial orbital rim, and inject into each of 5 sites (2 injections in each corrugator muscle and 1 in the procerus muscle). Ensure injected volume/dose is accurate and where feasible keep to a minimum. Avoid injection near the levator palpebrae superioris, particularly in patients with larger brow depressor complexes. Medial corrugator injections should be at least 1 cm above the bony supraorbital ridge. Do not inject toxin closer than 1 cm above the central eyebrow.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Spasticity (upper or lower limb): Use an appropriately sized sterile syringe and needle to administer intramuscularly. Although actual location of the injection sites can be determined by palpation, the use of an injection guiding technique (eg, electromyography or electrical stimulation) is recommended to target the injection sites. Do not administer &gt;0.5 mL for pediatric patients (lower limb spasticity) or &gt;1 mL for adult patients (upper or lower limb spasticity) in any single injection site.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7999305\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cervical dystonia:</b> Treatment of adults with cervical dystonia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Glabellar lines:</b> Temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and procerus muscle activity in adults &lt;65 years.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lower limb spasticity:</b> Treatment of lower limb spasticity in pediatric patients &ge;2 years.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Spasticity:</b> Treatment of spasticity in adults.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25808631\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Acquired nystagmus; Anal fissures; Hand dystonia; Sialorrhea (drooling) (adults); Spasticity of cerebral palsy (children/adolescents); Tardive dyskinesia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7999218\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Botulinum products are not interchangeable; potency differences may exist between the products.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9605445\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cervical dystonia:</b> Frequency not always defined.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Decreased heart rate</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Voice disorder (&le;28%), fatigue (12%), headache (11%), facial paresis (&le;11%), dizziness (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Increased serum glucose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Dysphagia (15% to 39%), xerostomia (13% to 39%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Antibody development (binding or neutralizing; 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Discomfort at injection site (13% to 22%), pain at injection site (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Myasthenia (11% to 56%), musculoskeletal pain (7%), amyotrophy (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Eye disease (&le;17%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dyspnea (3%; onset: ~1 week; duration: ~3 weeks)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Glabellar lines:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (9%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Contact dermatitis (2% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Hematuria (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Antibody development (&lt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Influenza (2% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Pain at injection site (3%), discomfort at injection site (2% to 3%), injection site reaction (2% to 3%), swelling at injection site (2% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Blepharoptosis (2%), eyelid edema (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasopharyngitis (10%), upper respiratory tract infection (3%), bronchitis (2% to 3%), cough (2% to 3%), pharyngolaryngeal pain (2% to 3%), sinusitis (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Upper limb spasticity:</b> Frequency not always defined.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (1% to 2%), syncope (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Myasthenia (2% to 4%), dizziness (3%), falling (3%), depression (2% to 3%), convulsions (2%), fatigue (2%), headache (2%), hypoesthesia (2%), seizure (partial; &le;2%), abnormal gait (&lt;1%), feeling of heaviness (&lt;1%), hypertonia (&lt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Increased serum triglycerides (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Constipation (2%), nausea (2%), diarrhea (1% to 2%), dysphagia (&lt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Bruise (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic Antibody development (7%; neutralizing: &le;4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (2%), influenza (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site reaction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Musculoskeletal pain (3%), back pain (2%), limb pain (2%), weakness (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasopharyngitis (4%), cough (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Accidental injury (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Lower limb spasticity: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infection: Influenza (children &amp; adolescents: 10% to 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Respiratory: Upper respiratory tract infection (children &amp; adolescents: 20%; adults: 2%), nasopharyngitis (children &amp; adolescents: 9% to 16%), cough (children &amp; adolescents: 7% to 14%), pharyngitis (children &amp; adolescents: 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Miscellaneous: Fever (children &amp; adolescents: 7% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cardiovascular: Hypertension (adults: 2%), peripheral edema (adults: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Central nervous system: Falling (adults: 6% to 9%, more frequent in patients &ge;65 years of age), epilepsy (&le;7%), seizure (&le;7%), myasthenia (5% to 7%), fatigue (adults: 1% to 4%), headache (adults: 3%), depression (adults: 2% to 3%), insomnia (adults: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gastrointestinal: Vomiting (children &amp; adolescents: 6% to 8%), nausea (children &amp; adolescents: 2% to 5%), viral gastroenteritis (children &amp; adolescents: 2% to 4%), constipation (adults: 2%), dysphagia (adults: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hematologic &amp; oncologic: Bruise (adults: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hepatic: Increased serum ALT (adults: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immunologic: Antibody development (4%; neutralizing: &le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infection: Varicella (children &amp; adolescents: 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Neuromuscular &amp; skeletal: Limb pain (6% to 7%), arthralgia (adults: 2% to 4%), back pain (adults: 3%), bone fracture (adults: 2%, wrist), weakness (adults: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Otic: Otic infection (children &amp; adolescents: 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Respiratory: Bronchitis (children &amp; adolescents: 7% to 8%), rhinitis (children &amp; adolescents: 5%), viral respiratory tract infection (children &amp; adolescents: 2% to 5%), oropharyngeal pain (children &amp; adolescents: 2% to 4%), flu-like symptoms (adults: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Any indication:</b> &lt;1%, postmarketing and/or case reports: Anaphylaxis, blurred vision, burning sensation, connective tissue disease (excessive granulation tissue), diplopia, dysarthria, dysphagia, erythema, facial paresis, hypersensitivity reaction, hypoesthesia, photophobia, urinary incontinence, xerophthalmia, vertigo</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9605334\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Known hypersensitivity (eg, anaphylaxis) to botulinum toxin or any component of the formulation, including cow milk protein; infection at the proposed injection site(s)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9605335\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylaxis/hypersensitivity reactions: Hypersensitivity and anaphylactic reactions may occur rarely; immediate treatment (including epinephrine 1 mg/mL) should be available.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antibody formation: Higher doses or more frequent administration may result in neutralizing antibody formation and loss of efficacy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular events: Rarely, arrhythmia and myocardial infarction have been reported with use of onabotulinumtoxinA (another botulinum toxin formulation), sometimes in patients with preexisting cardiovascular disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dysphagia: Common when used for cervical dystonia and may persist for several weeks after administration. In severe cases, patients may require alternative feeding methods (eg, feeding tube). Risk factors include smaller neck muscle mass, bilateral injections into the sternocleidomastoid muscle, or injections into the levator scapulae. Risk of aspiration resulting from severe dysphagia is increased in patients when swallowing is already compromised. Limiting the dose injected into the sternocleidomastoid muscle may reduce the occurrence of dysphagia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Systemic toxicity: <b>[US Boxed Warning]: Distant spread of botulinum toxin beyond the site of injection has been reported; dysphagia and breathing difficulties have occurred and may be life threatening; other symptoms reported include asthenia, blurred vision, diplopia, dysarthria, dysphonia, generalized muscle weakness, ptosis, and urinary incontinence which may develop within hours or weeks following injection.</b> Risk likely greatest in children treated for spasticity, but symptoms can also occur in adults treated for spasticity and other conditions. Systemic effects have occurred following use in approved and unapproved uses including lower than the maximum recommended total dose. Immediate medical attention required if respiratory, speech, or swallowing difficulties appear.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuromuscular disease: Use with caution in patients with neuromuscular diseases (eg, myasthenia gravis, Eaton-Lambert syndrome) and neuropathic disorders (eg, amyotrophic lateral sclerosis).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular diseases: Reduced blinking from injection of the orbicularis muscle can lead to corneal exposure and ulceration when treating blepharospasm. Retrobulbar hemorrhages may occur from needle penetration into orbit when treating strabismus; spatial disorientation, double vision, or past-pointing may occur if one or more extraocular muscles are paralyzed. Covering the affected eye may help. Careful testing of corneal sensation, avoidance of lower lid injections, and treatment of epithelial defects are necessary. Use caution in patients with angle closure glaucoma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory disease: Use extreme caution in patients with preexisting respiratory disease; treatment of cervical dystonia using botulinum toxin may weaken accessory muscles that are necessary for these patients to maintain adequate ventilation. Serious breathing difficulties, including respiratory failure, have been reported. Risk of aspiration resulting from severe dysphagia is increased in patients with decreased respiratory function.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Albumin: Product contains albumin and may carry a remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lactose: Product may contain lactose; do not administer to patients allergic to cow's milk protein.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Product interchangeability: Botulinum products (abobotulinumtoxinA, onabotulinumtoxinA, rimabotulinumtoxinB) are not interchangeable; potency units are specific to each preparation and cannot be compared or converted to any other botulinum product.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Temporary reduction in glabellar lines: Efficacy was not observed in older adults (&ge;65 years of age) and an increased frequency of ocular adverse events was reported in older adults compared to younger adults.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Lower limb spasticity: Safety and effectiveness of injection into proximal muscles of the lower limb have not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Chronic therapy: Long-term effects of chronic therapy unknown.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Injection site: Use with caution if there is inflammation or excessive weakness or atrophy at the proposed injection site(s); use is contraindicated if infection is present.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperhidrosis: Safety in the treatment of hyperhidrosis has not been established. The possibility of an immune reaction resulting from an intradermal injection is unknown.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Temporary reduction in glabellar lines: Appropriate use: Do not use more frequently than every 3 months. Patients with marked facial asymmetry, ptosis, excessive dermatochalasis, deep dermal scarring, thick sebaceous skin, or the inability to substantially lessen glabellar lines by physically spreading them apart were excluded from clinical trials. Use with caution in patients with surgical alterations to the facial anatomy. Reduced blinking from injection of the orbicularis muscle can lead to corneal exposure and ulceration. Spatial disorientation, double vision, or past pointing may occur if one or more extraocular muscles are paralyzed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298630\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349502\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9195&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: May enhance the neuromuscular-blocking effect of AbobotulinumtoxinA.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: May enhance the anticholinergic effect of AbobotulinumtoxinA.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents: AbobotulinumtoxinA may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OnabotulinumtoxinA: May enhance the adverse neuromuscular effect of AbobotulinumtoxinA.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RimabotulinumtoxinB: AbobotulinumtoxinA may enhance the adverse neuromuscular effect of RimabotulinumtoxinB. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9605331\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20517928\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if abobotulinumtoxinA is present in breast milk. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9605592\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Contains lactose; patients allergic to cow's milk protein should not receive product.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9605472\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">AbobotulinumtoxinA (previously known as botulinum toxin type A) is a neurotoxin produced by <i>Clostridium botulinum</i>, spore-forming anaerobic bacillus, which appears to affect only the presynaptic membrane of the neuromuscular junction in humans, where it prevents calcium-dependent release of acetylcholine and produces a state of denervation. Muscle inactivation persists until new fibrils grow from the nerve and form junction plates on new areas of the muscle-cell walls.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9605474\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Peak effect: Cervical dystonia: 2 to 4 weeks; Upper limb spasticity: 1 week </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Cervical dystonia, glabellar lines: &ge;4 months; Lower limb spasticity: &ge;5 &frac12; months; Upper limb spasticity: &ge;5 months</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Not expected to be present in peripheral blood at recommended doses following intramuscular (IM) injection</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322606\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Dysport Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 unit (1): $589.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 unit (1): $982.20</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26343897\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Dysport (AE, AR, AT, AU, BB, BE, BG, BR, CH, CO, CY, CZ, DE, DK, EE, ES, FI, FR, GR, HK, HU, IE, IL, IT, JO, KR, LB, LT, LU, LV, MT, MX, MY, NL, NO, NZ, PH, PL, PT, QA, RO, RU, SE, SG, SI, SK, TH, TR, VN, ZA);</li>\n      <li>Nabota (PH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Brisinda G, Albanese A, Cadeddu F, et al. Botulinum neurotoxin to treat chronic anal fissure: results of a randomized &quot;Botox vs. Dysport&quot; controlled trial. <i>Aliment Pharmacol Ther</i>. 2004;19(6):695-701.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abobotulinumtoxina-dysport-drug-information/abstract-text/15023172/pubmed\" target=\"_blank\" id=\"15023172\">15023172</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dysport (abobotulinumtoxinA) [prescribing information]. Basking Ridge, NJ: Ipsen Biopharmaceuticals; June 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hennings JM, Krause E, B&ouml;tzel K, Wetter TC. Successful treatment of tardive lingual dystonia with botulinum toxin: case report and review of the literature. <i>Prog Neuropsychopharmacol Biol Psychiatry</i>. 2008;32(5):1167-1171.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abobotulinumtoxina-dysport-drug-information/abstract-text/17936461/pubmed\" target=\"_blank\" id=\"17936461\">17936461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rapaport A, Sadeh M, Stein D, et al. Botulinum toxin for the treatment of oro-facial-lingual-masticatory tardive dyskinesia. <i>Mov Disord</i>. 2000;15(2):352-355.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abobotulinumtoxina-dysport-drug-information/abstract-text/10752596/pubmed\" target=\"_blank\" id=\"10752596\">10752596</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reddihough D, Erasmus CE, Johnson H, McKellar GM, Jongerius PH; Cerebral Palsy Institute. Botulinum toxin assessment, intervention and aftercare for paediatric and adult drooling: international consensus statement. <i>Eur J Neurol</i>. 2010;17 (suppl 2):109-121.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abobotulinumtoxina-dysport-drug-information/abstract-text/20633182/pubmed\" target=\"_blank\" id=\"20633182\">20633182</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ruben ST, Lee JP, O'Neil D, Dunlop I, Elston JS. The use of botulinum toxin for treatment of acquired nystagmus and oscillopsia. <i>Ophthalmology</i>. 1994;101(4):783-787.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abobotulinumtoxina-dysport-drug-information/abstract-text/8152776/pubmed\" target=\"_blank\" id=\"8152776\">8152776</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Simpson DM, Hallett M, Ashman EJ. et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. <i>Neurology</i>. 2016;86(19):1818-1826. doi: 10.1212/WNL.0000000000002560.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abobotulinumtoxina-dysport-drug-information/abstract-text/27164716/pubmed\" target=\"_blank\" id=\"27164716\">27164716</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Siproudhis L, S&eacute;bille V, Pigot F, H&eacute;mery P, Juguet F, Bellissant E. Lack of efficacy of botulinum toxin in chronic anal fissure. <i>Aliment Pharmacol Ther</i>. 2003;18(5):515-524.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abobotulinumtoxina-dysport-drug-information/abstract-text/12950424/pubmed\" target=\"_blank\" id=\"12950424\">12950424</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Slotema CW, van Harten PN, Bruggeman R, Hoek HW. Botulinum toxin in the treatment of orofacial tardive dyskinesia: a single blind study. <i>Prog Neuropsychopharmacol Biol Psychiatry</i>. 2008;32(2):507-509.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abobotulinumtoxina-dysport-drug-information/abstract-text/18022743/pubmed\" target=\"_blank\" id=\"18022743\">18022743</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vashishta R, Nguyen SA, White DR, Gillespie MB. Botulinum toxin for the treatment of sialorrhea: a meta-analysis. <i>Otolaryngol Head Neck Surg</i>. 2013;148(2):191-196. doi: 10.1177/0194599812465059.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abobotulinumtoxina-dysport-drug-information/abstract-text/23112272/pubmed\" target=\"_blank\" id=\"23112272\">23112272</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yiannakopoulou E. Botulinum toxin and anal fissure: efficacy and safety systematic review. <i>Int J Colorectal Dis</i>. 2012;27(1):1-9. doi: 10.1007/s00384-011-1286-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abobotulinumtoxina-dysport-drug-information/abstract-text/21822595/pubmed\" target=\"_blank\" id=\"21822595\">21822595</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9195 Version 124.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F9605326\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F7999220\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F51235505\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F7999304\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F9605588\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F48838379\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F9605589\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F9605590\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F9605591\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F9605595\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F9605328\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F9605327\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F9605593\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F7999305\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25808631\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F7999218\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F9605445\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F9605334\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F9605335\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298630\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F9349502\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F9605331\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20517928\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F9605592\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F9605472\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F9605474\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322606\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F26343897\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9195|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=abobotulinumtoxina-dysport-patient-drug-information\" class=\"drug drug_patient\">AbobotulinumtoxinA (Dysport): Patient drug information</a></li><li><a href=\"topic.htm?path=abobotulinumtoxina-dysport-pediatric-drug-information\" class=\"drug drug_pediatric\">AbobotulinumtoxinA (Dysport): Pediatric drug information</a></li></ul></div></div>","javascript":null}